N/A
Completed N=236
Otoacoustic Emission Suppression Study
Neonatal Hearing Loss
Source: ClinicalTrials.gov NCT04749524 ↗
Enrolled (actual)
236
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcomePrimary: Otoacoustic Suppression Measure — 1.95; 1.33; 2.48; 0.36 dB - Unitless Difference in dB SPL
Summary
The focus of this project is on a physiologic auditory response called the Medial Olivocochlear Reflex (MOCR) that assesses peripheral neural function. While neural hearing loss is a significant auditory disorder in patients of all ages, more than 50% of newborn infants are screened with a technology that is not sensitive to abnormalities in neural function. The development of a time-efficient and sensitive test system to assess the MOCR will provide significant benefit to infants and patients of all ages with neural deficits who would otherwise go undetected.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Otoacoustic Suppression Measure |
1.95; 1.33; 2.48; 0.36; 1.57; 1.79 | — |
Eligibility Criteria
Inclusion Criteria
- Normal middle-ear function
- Present TEOAEs.
Exclusion Criteria
- Atresia or other external ear abnormalities not allowing recording of OAEs
Data sourced from ClinicalTrials.gov (NCT04749524). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.